Clinical Trial Update: A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TACE combined with atezolizumab plus bevacizumab versus TACE alone in untreated hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Transarterial chemoembolization (chemotherapy with embolization (various agents))

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING